FibroGen Depreciation And Amortization vs Income Tax Expense Analysis
| FGEN Stock | USD 1.14 0.01 0.88% |
FibroGen financial indicator trend analysis is much more than just examining FibroGen latest accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether FibroGen is a good investment. Please check the relationship between FibroGen Depreciation And Amortization and its Income Tax Expense accounts. Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in FibroGen. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in income. To learn how to invest in FibroGen Stock, please use our How to Invest in FibroGen guide.
Depreciation And Amortization vs Income Tax Expense
Depreciation And Amortization vs Income Tax Expense Correlation Analysis
The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of FibroGen Depreciation And Amortization account and Income Tax Expense. At this time, the significance of the direction appears to have significant contrarian relationship.
The correlation between FibroGen's Depreciation And Amortization and Income Tax Expense is -0.3. Overlapping area represents the amount of variation of Depreciation And Amortization that can explain the historical movement of Income Tax Expense in the same time period over historical financial statements of FibroGen, assuming nothing else is changed. The correlation between historical values of FibroGen's Depreciation And Amortization and Income Tax Expense is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Depreciation And Amortization of FibroGen are associated (or correlated) with its Income Tax Expense. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Income Tax Expense has no effect on the direction of Depreciation And Amortization i.e., FibroGen's Depreciation And Amortization and Income Tax Expense go up and down completely randomly.
Correlation Coefficient | -0.3 |
| Relationship Direction | Negative |
| Relationship Strength | Insignificant |
Depreciation And Amortization
The systematic reduction in the recorded value of an intangible asset. This includes the allocation of the cost of tangible assets to periods in which the assets are used, representing the expense related to the wear and tear, deterioration, or obsolescence of physical assets and intangible assets over their useful lives.Income Tax Expense
Most indicators from FibroGen's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into FibroGen current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in FibroGen. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in income. To learn how to invest in FibroGen Stock, please use our How to Invest in FibroGen guide.As of the 3rd of May 2024, Selling General Administrative is likely to drop to about 82.7 M. In addition to that, Tax Provision is likely to drop to about 29.4 K
| 2021 | 2022 | 2023 | 2024 (projected) | Interest Expense | 2.2M | 1.4M | 15.5M | 16.3M | Depreciation And Amortization | 14.8M | 18.2M | 9.9M | 9.5M |
FibroGen fundamental ratios Correlations
Click cells to compare fundamentals
FibroGen Account Relationship Matchups
High Positive Relationship
High Negative Relationship
FibroGen fundamental ratios Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Total Assets | 857.4M | 826.8M | 773.8M | 610.1M | 423.5M | 665.2M | |
| Short Long Term Debt Total | 51.1M | 37.7M | 99.7M | 89.9M | 170.5M | 103.2M | |
| Other Current Liab | 83.8M | 119.5M | 172.6M | 219.4M | 172.9M | 86.8M | |
| Total Current Liabilities | 102.7M | 163.2M | 225.5M | 273.6M | 217.7M | 128.8M | |
| Total Stockholder Equity | 516.1M | 422.2M | 209.1M | (21.4M) | (204.2M) | (194.0M) | |
| Other Liab | 162.8M | 178.1M | 212.8M | 241.4M | 277.6M | 147.1M | |
| Property Plant And Equipment Net | 82.3M | 63.3M | 120.2M | 100.5M | 81.4M | 89.5M | |
| Current Deferred Revenue | 490K | 6.5M | 15.9M | 13.1M | 12.7M | 10.0M | |
| Net Debt | (75.2M) | (640.7M) | (71.5M) | (65.8M) | 56.8M | 59.6M | |
| Retained Earnings | (784.7M) | (974.0M) | (1.3B) | (1.6B) | (1.8B) | (1.7B) | |
| Accounts Payable | 6.1M | 24.8M | 26.1M | 30.8M | 18.0M | 13.0M | |
| Cash | 126.3M | 678.4M | 171.2M | 155.7M | 113.7M | 108.0M | |
| Non Current Assets Total | 154.9M | 71.7M | 299.8M | 117.3M | 92.0M | 146.7M | |
| Non Currrent Assets Other | 11.4M | 5.5M | 8.0M | 7.4M | 3.6M | 6.4M | |
| Other Assets | 9.5M | 38.1M | 8.0M | 6.9M | 1.0 | 0.95 | |
| Long Term Debt | 17.2M | 16.8M | 16.8M | 71.9M | 64.7M | 46.3M | |
| Cash And Short Term Investments | 533.8M | 686.5M | 405.2M | 422.0M | 235.6M | 404.9M | |
| Net Receivables | 28.5M | 41.9M | 17.4M | 16.3M | 41.1M | 25.9M | |
| Common Stock Total Equity | 854K | 877K | 914K | 929K | 1.1M | 716.1K | |
| Common Stock Shares Outstanding | 86.6M | 89.9M | 92.3M | 93.6M | 97.3M | 78.2M | |
| Short Term Investments | 407.5M | 8.1M | 234.0M | 266.3M | 121.9M | 165.1M | |
| Liabilities And Stockholders Equity | 857.4M | 826.8M | 773.8M | 610.1M | 423.5M | 665.2M | |
| Non Current Liabilities Total | 219.2M | 222.2M | 319.2M | 338.0M | 368.1M | 261.8M | |
| Other Current Assets | 133.4M | 1.8M | 5.1M | 4.4M | 13.4M | 17.1M | |
| Other Stockholder Equity | 1.3B | 1.4B | 1.5B | 1.5B | 1.6B | 1.0B | |
| Total Liab | 322.0M | 385.4M | 544.7M | 611.6M | 585.7M | 390.6M | |
| Property Plant And Equipment Gross | 82.3M | 63.3M | 120.2M | 100.5M | 253.1M | 138.8M | |
| Total Current Assets | 702.5M | 755.1M | 474.1M | 492.8M | 331.6M | 463.5M | |
| Accumulated Other Comprehensive Income | (747K) | (4.5M) | (4.2M) | (5.7M) | (6.9M) | (6.5M) | |
| Short Term Debt | 12.4M | 12.3M | 11.0M | 10.3M | 14.1M | 19.1M | |
| Common Stock | 877K | 914K | 929K | 942K | 988K | 773.7K | |
| Property Plant Equipment | 42.7M | 33.6M | 120.2M | 100.9M | 90.8M | 86.7M | |
| Net Tangible Assets | 516.1M | 422.2M | 209.1M | (21.4M) | (19.3M) | (18.3M) | |
| Long Term Investments | 61.1M | 244K | 171.6M | 9.4M | 5.3M | 5.0M | |
| Retained Earnings Total Equity | (715.8M) | (784.7M) | (974.0M) | (1.3B) | (1.1B) | (1.2B) | |
| Capital Surpluse | 1.2B | 1.3B | 1.4B | 1.5B | 1.7B | 1.2B |
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards FibroGen in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, FibroGen's short interest history, or implied volatility extrapolated from FibroGen options trading.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in FibroGen. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in income. To learn how to invest in FibroGen Stock, please use our How to Invest in FibroGen guide.Note that the FibroGen information on this page should be used as a complementary analysis to other FibroGen's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Premium Stories module to follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope.
Complementary Tools for FibroGen Stock analysis
When running FibroGen's price analysis, check to measure FibroGen's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy FibroGen is operating at the current time. Most of FibroGen's value examination focuses on studying past and present price action to predict the probability of FibroGen's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move FibroGen's price. Additionally, you may evaluate how the addition of FibroGen to your portfolios can decrease your overall portfolio volatility.
| Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals | |
| Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine | |
| ETFs Find actively traded Exchange Traded Funds (ETF) from around the world | |
| Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges | |
| Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules | |
| Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years | |
| Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets | |
| Volatility Analysis Get historical volatility and risk analysis based on latest market data | |
| Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Investing Opportunities Build portfolios using our predefined set of ideas and optimize them against your investing preferences | |
| Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments |
Is FibroGen's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of FibroGen. If investors know FibroGen will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about FibroGen listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 0.536 | Earnings Share (2.92) | Revenue Per Share 1.518 | Quarterly Revenue Growth (0.21) | Return On Assets (0.36) |
The market value of FibroGen is measured differently than its book value, which is the value of FibroGen that is recorded on the company's balance sheet. Investors also form their own opinion of FibroGen's value that differs from its market value or its book value, called intrinsic value, which is FibroGen's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because FibroGen's market value can be influenced by many factors that don't directly affect FibroGen's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between FibroGen's value and its price as these two are different measures arrived at by different means. Investors typically determine if FibroGen is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, FibroGen's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.